Dr. Michael Alonso is a Scientific Co-Founder, and Vice President of Immunology & Pharmacology at Bolt Biotherapeutics, a biotechnology company developing immunotherapies that activate myeloid cells. He discusses targeting tumors by covering them in "eat me" signals, considerations for moving drugs into the clinic, and building teams in biotech.